About Cenexum

The company develops wireless neural interfacing technology that enables bi-directional communication with nerve tissue. This technology powers next-generation neuromodulation devices, facilitating the treatment of neurological and psychiatric disorders.

```xml <problem> Existing electrical neurostimulation therapies, such as Deep Brain Stimulation (DBS), Spinal Cord Stimulation (SCS), and Vagal Nerve Stimulation (VNS), often require highly invasive procedures, implanted batteries, and physician intervention for optimal treatment adjustment. These limitations restrict broader usage and can lead to complications. </problem> <solution> Cenexum is developing a wirelessly powered neural interfacing technology that enables bi-directional communication with nerve tissue through a miniature, intelligent implantable device. This device facilitates bio-inspired data processing and stimulation in a closed-loop system, allowing for personalized adjustment of neurostimulation. Wireless communication between the microscale implant and an external unit eliminates the need for implanted batteries, reducing surgical complexity and potential complications. The technology aims to provide safe, effective, and convenient treatment options for neurological and psychiatric disorders. </solution> <features> - Miniatured implantable device enabling bio-inspired data processing and stimulation in a closed loop - Wireless communication via mild electrical impulses between microscale-implant device and external unit - Wirelessly powered implantable device eliminating the need for implanted batteries - Potential for networking multiple devices to integrate data from various parts of the central and peripheral nervous system - AI and ML-driven data processing for personalized neurostimulation adjustments - Suitable for implantation at the core location of the disease to treat </features> <target_audience> The primary target audience includes patients with neurological and psychiatric disorders, such as chronic pain, depression, movement disorders, Parkinson’s disease, Alzheimer’s disease, and epilepsy, as well as neurosurgeons and medical professionals specializing in neuromodulation therapies. </target_audience> ```

What does Cenexum do?

Where is Cenexum located?

Cenexum is based in Danmark.

When was Cenexum founded?

Cenexum was founded in 2022.

Location

Danmark

Founded

2022

Employees

8 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Cenexum

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

cenexum.com 200+

Founded 2022 – Danmark

Funding

No funding information available.

Team (5+)

No team information available.

Company Description

Problem

Existing electrical neurostimulation therapies, such as Deep Brain Stimulation (DBS), Spinal Cord Stimulation (SCS), and Vagal Nerve Stimulation (VNS), often require highly invasive procedures, implanted batteries, and physician intervention for optimal treatment adjustment. These limitations restrict broader usage and can lead to complications.

Solution

Cenexum is developing a wirelessly powered neural interfacing technology that enables bi-directional communication with nerve tissue through a miniature, intelligent implantable device. This device facilitates bio-inspired data processing and stimulation in a closed-loop system, allowing for personalized adjustment of neurostimulation. Wireless communication between the microscale implant and an external unit eliminates the need for implanted batteries, reducing surgical complexity and potential complications. The technology aims to provide safe, effective, and convenient treatment options for neurological and psychiatric disorders.

Features

Miniatured implantable device enabling bio-inspired data processing and stimulation in a closed loop

Wireless communication via mild electrical impulses between microscale-implant device and external unit

Wirelessly powered implantable device eliminating the need for implanted batteries

Potential for networking multiple devices to integrate data from various parts of the central and peripheral nervous system

AI and ML-driven data processing for personalized neurostimulation adjustments

Suitable for implantation at the core location of the disease to treat

Target Audience

The primary target audience includes patients with neurological and psychiatric disorders, such as chronic pain, depression, movement disorders, Parkinson’s disease, Alzheimer’s disease, and epilepsy, as well as neurosurgeons and medical professionals specializing in neuromodulation therapies.